Minireview: Were the IGF Signaling Inhibitors All Bad?
暂无分享,去创建一个
[1] A. Carrato,et al. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] B. Shewchuk,et al. Growth hormone enhances LNCaP prostate cancer cell motility , 2015, Endocrine research.
[3] T. Choueiri,et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. , 2015, The Lancet. Oncology.
[4] G. Scagliotti,et al. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] Anne Wallace,et al. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer , 2015, Clinical Cancer Research.
[6] Fei Huang,et al. IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines , 2014, Molecular Cancer Therapeutics.
[7] F. Shepherd,et al. Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial , 2014, Experimental Hematology & Oncology.
[8] J. Baselga,et al. Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial , 2014, Clinical Cancer Research.
[9] Ladan Fazli,et al. The Tyrphostin NT157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer , 2014, Molecular Cancer Therapeutics.
[10] J. Berlin,et al. A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.
[11] Edward S. Kim,et al. Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors , 2014, Clinical Cancer Research.
[12] P. Houghton,et al. Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma , 2014, PloS one.
[13] William Pao,et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer , 2014, Nature Medicine.
[14] Keunchil Park,et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] E. Santoni-Rugiu,et al. Insulin-like growth factor receptor 1 mRNA expression as a prognostic marker in advanced non-small cell lung cancer. , 2014, Anticancer research.
[16] P. Cohen,et al. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice. , 2014, The Journal of endocrinology.
[17] M. Dowsett,et al. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] H. Werner,et al. Insulin receptor compensates for IGF1R inhibition and directly induces mitogenic activity in prostate cancer cells , 2014, Endocrine connections.
[19] G. Leone,et al. Stat5 Regulates the Phosphatidylinositol 3-Kinase/Akt1 Pathway during Mammary Gland Development and Tumorigenesis , 2014, Molecular and Cellular Biology.
[20] V. Macaulay,et al. IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination , 2013, Oncogene.
[21] P. Rejto,et al. Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871) , 2013, Molecular Cancer Therapeutics.
[22] D. Leroith,et al. Insulin Receptor Phosphorylation by Endogenous Insulin or the Insulin Analog AspB10 Promotes Mammary Tumor Growth Independent of the IGF-I Receptor , 2013, Diabetes.
[23] M. Herlyn,et al. Therapeutic destruction of insulin receptor substrates for cancer treatment. , 2013, Cancer research.
[24] J. Frasor,et al. Growth hormone potentiates 17β-estradiol-dependent breast cancer cell proliferation independently of IGF-I receptor signaling. , 2013, Endocrinology.
[25] C. Fuchs,et al. Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor , 2013, Clinical Cancer Research.
[26] F. Bertucci,et al. Contrasted Outcomes to Gefitinib on Tumoral IGF1R Expression in Head and Neck Cancer Patients Receiving Postoperative Chemoradiation (GORTEC Trial 2004-02) , 2012, Clinical Cancer Research.
[27] D. Yee. Insulin-like growth factor receptor inhibitors: baby or the bathwater? , 2012, Journal of the National Cancer Institute.
[28] D. Yee,et al. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. , 2012, Cancer research.
[29] J. Desai,et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] G. Bray,et al. Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study , 2012, Diabetes Care.
[31] J. Livingstone,et al. Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature , 2011, Oncogene.
[32] M. Dowsett,et al. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. , 2011, Endocrine-related cancer.
[33] I. Ellis,et al. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines , 2011, Breast Cancer Research.
[34] J. Baselga,et al. A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors , 2011, Clinical Cancer Research.
[35] Federica Madia,et al. Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans , 2011, Science Translational Medicine.
[36] S. Koujak,et al. Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer , 2010, Molecular Cancer Therapeutics.
[37] Adrian V. Lee,et al. Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition , 2010, Clinical Cancer Research.
[38] G. Hammer,et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma , 2010, Cancer Chemotherapy and Pharmacology.
[39] D. Yee,et al. Inhibition of Cancer Cell Proliferation and Metastasis by Insulin Receptor Downregulation , 2010, Oncogene.
[40] S. Schuetze,et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. , 2010, The Lancet. Oncology.
[41] A. Tolcher,et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] L. Paz-Ares,et al. Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[43] D. Yee,et al. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival , 2009, Oncogene.
[44] J. Petrik,et al. Reversibility and recurrence of IGF-IR-induced mammary tumors , 2009, Oncogene.
[45] S. Novello,et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] L. Crinò,et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] D. Yee,et al. Sequencing of Type I Insulin-Like Growth Factor Receptor Inhibition Affects Chemotherapy Response In vitro and In vivo , 2009, Clinical Cancer Research.
[48] N. Møller,et al. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. , 2009, Endocrine reviews.
[49] D. Sachdev. Regulation of Breast Cancer Metastasis by IGF Signaling , 2008, Journal of Mammary Gland Biology and Neoplasia.
[50] R. Nicholson,et al. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance , 2008, Breast Cancer Research and Treatment.
[51] R. Fonseca,et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] P. Jänne,et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients , 2008, British Journal of Cancer.
[53] A. Adjei,et al. Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors , 2007, Clinical Cancer Research.
[54] C. J. Barnes,et al. Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer , 2007, Clinical Cancer Research.
[55] S. Byron,et al. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells , 2006, British Journal of Cancer.
[56] D. Yee,et al. The IGF system and breast cancer. , 2001, Endocrine-related cancer.
[57] A. Renehan,et al. Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3 , 1999 .
[58] M. Spitz,et al. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. , 1999, Journal of the National Cancer Institute.
[59] David J Hunter,et al. Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.
[60] I. Kerr,et al. Janus Kinase-dependent Activation of Insulin Receptor Substrate 1 in Response to Interleukin-4, Oncostatin M, and the Interferons* , 1997, The Journal of Biological Chemistry.
[61] C. Osborne,et al. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. , 1989, Molecular endocrinology.
[62] C. Osborne,et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. , 1989, The Journal of clinical investigation.
[63] R. Shiu,et al. Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture. , 1984, Cancer research.
[64] G. Smith,et al. Identification of somatomedin-like polypeptides produced by mammary tumors of BALB/c mice. , 1980, Cancer research.
[65] F. Liu,et al. Interaction of somatomedin-C with an antibody directed against the synthetic C-peptide region of insulin-like growth factor-I. , 1980, The Journal of clinical endocrinology and metabolism.
[66] J. Guevara-Aguirre,et al. Obesity, diabetes and cancer: insight into the relationship from a cohort with growth hormone receptor deficiency , 2014, Diabetologia.
[67] 向原 徹. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression , 2011 .
[68] D. Hanahan,et al. Inaugural Article: Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy , 2010 .
[69] Xia Han,et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. , 2009, Cancer research.
[70] M. Stampfer,et al. A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. , 2000, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[71] Stampfer,et al. RESPONSE: Re: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3. , 1999, Journal of the National Cancer Institute.